Search Publications
Search

45 results for: Capability: Patent Litigation

Clear Results
October 31, 2025

Federal Circuit Holds That Patentee’s Disavowal of Claim Construction Warrants Reversal of Summary Judgment

The Intellectual Property Strategist
August 31, 2025

Federal Circuit: Board Erred in Finding No Likelihood of Confusion Between KIST and SUNKIST Marks

The Intellectual Property Strategist
May 2025

Federal Circuit Examines Written Description Requirements for U.S. Patent Application Publications Used as Prior Art Under Pre-AIA

Intellectual Property Strategist
April 18, 2025

Fed. Circ.'s PTAB Ruling Highlights Obsolete Rationale

Law360
March 1, 2025

Federal Circuit: PTAB Jurisdiction Exists Over Expired Patents

The Intellectual Property Strategist
January 1, 2025

Federal Circuit: District Courts May Impose Deterrence Sanctions Even After They Had Already Awarded Attorney Fees and Costs Under 35 U.S.C. § 285

The Intellectual Property Strategist
November 22, 2024

This Lawyer’s Life: Gregory Diskant, Big Law Leadership and Litigation

New York City Bar Association Podcast
August 1, 2022

Coronavirus (COVID-19) Resource Center

May 3, 2022

Federal Circuit Affirms Precedential Opinion Panel Decision Limiting the Circumstances In Which the Board Should Raise Sua Sponte Patentability Issues Against Proposed Substitute Claims

The Intellectual Property Strategist
January 10, 2022

Pair of Federal Circuit Decisions Address Standing to Appeal Adverse IPR Decision

The Intellectual Property Strategist
September 9, 2021

Federal Circuit Clarifies Pleading Requirements for Patent Cases and Affirms Grant of Summary Judgement of Invalidity Under 35 U.S.C. §101

The Intellectual Property Strategist
March 4, 2021

Federal Circuit: Texas Court Abused Its Discretion By Delaying On Venue Transfer Motion While Proceeding With the Merits of the Case (March 2021)

The Intellectual Property Strategist
February 18, 2021

Federal Circuit Axes Amgen Antibody Patents, Finding Lack of Enablement

February 1, 2021

2021 Biosimilar Approval and Litigation Update

January 8, 2021

What’s Ahead in 2021 for Reverse-Payment Settlement Litigation

Bloomberg Law
January 6, 2021

Federal Circuit: Post-Employment Assignment Clause Void Under California Law (January 2021)

The Intellectual Property Strategist
November 19, 2020

For the First Time Since TC Heartland, the Federal Circuit Addresses Venue in an ANDA Case – the Holding May Also Impact BPCIA Litigation

July 9, 2020

Federal Circuit Holds That Amendments to Biosimilar’s BLA Do Not Trigger Anew BPCIA’s Notice of Commercial Marketing Provision

May 14, 2019

Federal Circuit Strikes Down Diagnostic Patent in Latest § 101 Decision

December 11, 2018

Fed. Circ. Provides Clarity On Patent Term Questions

December 10, 2018

Federal Circuit Clarifies Law of Obviousness-Type Double Patenting: Patent Term Extension and Patent Term Due to URAA Are Safe from Gilead v. Natco

August 22, 2018

Beyond the Presumption Against Extraterritoriality

August 1, 2018

PTAB and Bar Prepare for Aftermath of Supreme Court’s SAS Decision

April 13, 2018

Fed. Circ. Case May Change Biosimilar IPR Strategy

March 13, 2018

USPTO Adopts Amgen v. Sanofi, Excises “Newly Characterized Antigen” Test from its Written Description Guidance for Antibody Claims

February 1, 2018

Patent dance remains on point

December 15, 2017

Federal Circuit: BPCIA Preempts State Law In Biosimilar Litigation

December 8, 2017

Mixed Results as IPR Petitions for Biosimilars Soar

October 5, 2017

A New Strain Of Inequitable Conduct Litigation

December 22, 2016

Discontent At Fed. Circ. Grows Post Cuozzo

April 27, 2016

A Breakthrough Technology is Caught in an Epic Patent Battle

March 16, 2016

Biosimilar Makers Turn To IPRs Despite Mixed Results

November 13, 2015

Impact of Nautilus on Biotech and Pharmaceutical Patents

October 27, 2015

TPP Biologics Exclusivity Period Maintains The Status Quo

June 2015

Biobetters: The Advantages and Challenges of Being Better

June 18, 2015

Mayo Test Dooms Breakthrough Biotech Invention

June 2015

New Targets in the Crosshairs: A forum to invalidate patents is now being used on biotech firms

October 2014

If High Court Reverses Teva, Litigation Costs May Increase

February 2012

FDA Issues Draft Guidelines for Biosimilars

January 2012

Partnering With The Feds For IP Enforcement: Part 1

June 2011

Supreme Court Decision: Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems, Inc.

May 2011

IP Audits: Making the Most of Your Intellectual Property

April 9, 2010

Federal Circuit Reinvigorates the Written Description Requirement

June 2009

On Appeal Alert: Federal Circuit Grants Mandamus on Motion to Transfer Venue

Spring 2008

IP OnTrial